Search Results

Suggested Topics within your search.
Refine Results
  1. 1
    <i>In Vitro</i> and <i>In Vivo</i> Activity of Cabozantinib (XL184), an Inhibitor of RET, MET, and VEGFR2, in a Model of Medullary Thyroid Cancer

    <i>In Vitro</i> and <i>In Vivo</i> Activity of Cabozantinib (XL184), an Inhibitor of RET, MET, and VEGFR2, in a Model of Medullary Thyroid Cancer by Frauke Bentzien, Marcus Zuzow, Nathan Heald, Anna Gibson, Yongchang Shi, Leanne Goon, Peiwen Yu, Stefan Engst, Wentao Zhang, Donghui Huang, Lora Zhao, Valentina Vysotskaia, Felix Chu, Rhea A. Bautista, Belinda Cancilla, Peter Lamb, Alison Joly, F. Michael Yakes

    Published 2013
    Get full text
    Artigo
    Save to List
    Saved in:
  2. 2
    Potent antitumor activity of cabozantinib, a c‐<scp>MET</scp> and <scp>VEGFR</scp>2 inhibitor, in a colorectal cancer patient‐derived tumor explant model

    Potent antitumor activity of cabozantinib, a c‐<scp>MET</scp> and <scp>VEGFR</scp>2 inhibitor, in a colorectal cancer patient‐derived tumor explant model by Eun‐Kee Song, WM. Tai, Wells A. Messersmith, Stacey M. Bagby, Alicia Purkey, Kevin S. Quackenbush, Todd M. Pitts, Guoliang Wang, Patrick J. Blatchford, Rachel Yahn, Jeffrey Kaplan, Aik Choon Tan, Chloé E. Atreya, Gail Eckhardt, Robin Kate Kelley, Alan P. Venook, Eunice L. Kwak, David P. Ryan, John J. Arcaroli

    Published 2014
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  3. 3
    Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma

    Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma by Lijun Zhou, Xian-De Liu, Mingli Sun, Xian Zhang, Polina German, Shanshan Bai, Zhiyong Ding, Nizar M. Tannir, Christopher G. Wood, Surena F. Matin, José A. Karam, Pheroze Tamboli, Kanishka Sircar, Priya Rao, Erinn B. Rankin, Douglas Laird, Anh Hoang, Cheryl L. Walker, Amato J. Giaccia, Eric Jonasch

    Published 2015
    Get full text
    Artigo
    Save to List
    Saved in:
  4. 4
    Profile of cabozantinib and its potential in the treatment of advanced medullary thyroid cancer

    Profile of cabozantinib and its potential in the treatment of advanced medullary thyroid cancer by Richard de Boer, Christopher D. Hart

    Published 2013
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  5. 5
    Mineralocorticoid receptor suppresses cancer progression and the Warburg effect by modulating the miR‐338‐3p‐PKLR axis in hepatocellular carcinoma

    Mineralocorticoid receptor suppresses cancer progression and the Warburg effect by modulating the miR‐338‐3p‐PKLR axis in hepatocellular carcinoma by Hui Nie, Jun Li, Xiaomei Yang, Cao Qing-zhen, Mingxuan Feng, Feng Xue, Lin Wei, Wenxin Qin, Jianren Gu, Qiang Xia, Zhigang Zhang

    Published 2015
    Get full text
    Artigo
    Save to List
    Saved in:
  6. 6
    Thyroid Carcinoma, Version 2.2014

    Thyroid Carcinoma, Version 2.2014 by R. Michael Tuttle, Robert I. Haddad, Douglas W. Ball, David R. Byrd, Paxton V. Dickson, Quan‐Yang Duh, Hormoz Ehya, Megan R. Haymart, Carl K. Hoh, Jason P. Hunt, Andrei Iagaru, Fouad Kandeel, Peter Kopp, Dominick Lamonica, William M. Lydiatt, Judith C. McCaffrey, Jeffrey F. Moley, Lee Parks, Christopher D. Raeburn, John A. Ridge, Matthew D. Ringel, Randall P. Scheri, Jatin P. Shah, Steven I. Sherman, Cord Sturgeon, Steven G. Waguespack, Thomas J. Wang, Lori J. Wirth, K Hoffmann, Miranda Hughes

    Published 2014
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  7. 7
    Cabozantinib (XL184) Inhibits Growth and Invasion of Preclinical TNBC Models

    Cabozantinib (XL184) Inhibits Growth and Invasion of Preclinical TNBC Models by Mansoureh Sameni, Elizabeth A. Tovar, Curt J. Essenburg, Anita Chalasani, Erik S. Linklater, Andrew Borgman, David Cherba, Arulselvi Anbalagan, Mary E. Winn, Carrie R. Graveel, Bonnie F. Sloane

    Published 2015
    Get full text
    Artigo
    Save to List
    Saved in:
  8. 8
    New molecularly targeted therapies against advanced hepatocellular carcinoma: From molecular pathogenesis to clinical trials and future directions

    New molecularly targeted therapies against advanced hepatocellular carcinoma: From molecular pathogenesis to clinical trials and future directions by Makoto Chuma, Katsumi Terashita, Naoya Sakamoto

    Published 2014
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  9. 9
    A Phase I Study of Cabozantinib (XL184) in Patients with Differentiated Thyroid Cancer

    A Phase I Study of Cabozantinib (XL184) in Patients with Differentiated Thyroid Cancer by Maria E. Cabanillas, Marcia S. Brose, Jaymes Holland, Kimberly Ferguson, Steven I. Sherman

    Published 2014
    Get full text
    Artigo
    Save to List
    Saved in:
  10. 10
    New Therapies for Dedifferentiated Papillary Thyroid Cancer

    New Therapies for Dedifferentiated Papillary Thyroid Cancer by Poupak Fallahi, Valeria Mazzi, Roberto Vita, Silvia Ferrari, Gabriele Materazzi, David Galleri, Salvatore Benvenga, Paolo Miccoli, Alessandro Antonelli

    Published 2015
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  11. 11
    Chemoembolization and Radioembolization for Hepatocellular Carcinoma

    Chemoembolization and Radioembolization for Hepatocellular Carcinoma by Riad Salem, Robert J. Lewandowski

    Published 2013
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  12. 12
    Osteonecrosis of the jaw in a patient receiving cabozantinib

    Osteonecrosis of the jaw in a patient receiving cabozantinib by R Marino, Fabio Orlandi, Federico Arecco, S Gandolfo, Monica Pentenero

    Published 2014
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  13. 13
    Cabozantinib in Chemotherapy-Pretreated Metastatic Castration-Resistant Prostate Cancer: Results of a Phase II Nonrandomized Expansion Study

    Cabozantinib in Chemotherapy-Pretreated Metastatic Castration-Resistant Prostate Cancer: Results of a Phase II Nonrandomized Expansion Study by Matthew R. Smith, Christopher J. Sweeney, Paul G. Corn, Dana E. Rathkopf, David C. Smith, Maha Hussain, Daniel J. George, Celestia S. Higano, Andrea Harzstark, Oliver Sartor, Nicholas J. Vogelzang, Michael S. Gordon, Johann S. de Bono, Naomi B. Haas, Christopher J. Logothetis, Aymen Elfiky, Christian Scheffold, A. Douglas Laird, Frauke Schimmöller, Ethan Basch, Howard I. Scher

    Published 2014
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  14. 14
    <i><scp>RET</scp></i> fusion gene: Translation to personalized lung cancer therapy

    <i><scp>RET</scp></i> fusion gene: Translation to personalized lung cancer therapy by Takashi Kohno, Koji Tsuta, Katsuya Tsuchihara, Takashi Nakaoku, Kiyotaka Yoh, Kōichi Goto

    Published 2013
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  15. 15
    The Effects of Four Different Tyrosine Kinase Inhibitors on Medullary and Papillary Thyroid Cancer Cells

    The Effects of Four Different Tyrosine Kinase Inhibitors on Medullary and Papillary Thyroid Cancer Cells by Hans H G Verbeek, Maria M. Alves, Jan‐Willem B. de Groot, Jan Osinga, John Th. M. Plukker, Thera P. Links, Robert M.W. Hofstra

    Published 2011
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  16. 16
    Medullary Thyroid Cancer in the Era of Tyrosine Kinase Inhibitors: To Treat or Not to Treat—and With Which Drug—Those Are the Questions

    Medullary Thyroid Cancer in the Era of Tyrosine Kinase Inhibitors: To Treat or Not to Treat—and With Which Drug—Those Are the Questions by Maria E. Cabanillas, Mimi I. Hu, Camilo Jiménez

    Published 2014
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  17. 17
    AXL Inhibition Sensitizes Mesenchymal Cancer Cells to Antimitotic Drugs

    AXL Inhibition Sensitizes Mesenchymal Cancer Cells to Antimitotic Drugs by Catherine Wilson, Xiaofen Ye, Thinh Pham, Eva Lin, Sara M. Chan, Erin McNamara, Richard M. Neve, Lisa D. Belmont, Hartmut Koeppen, Robert L. Yauch, Avi Ashkenazi, Jeff Settleman

    Published 2014
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  18. 18
    The novel c-Met inhibitor cabozantinib overcomes gemcitabine resistance and stem cell signaling in pancreatic cancer

    The novel c-Met inhibitor cabozantinib overcomes gemcitabine resistance and stem cell signaling in pancreatic cancer by Carina Hage, Vanessa Rausch, Nathalia A. Giese, Thomas Giese, Frank Schönsiegel, Sabrina Labsch, Clifford C. Nwaeburu, J Mattern, Jury Gladkich, Ingrid Herr

    Published 2013
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  19. 19
    In the clinic: ongoing clinical trials evaluating c-MET-inhibiting drugs

    In the clinic: ongoing clinical trials evaluating c-MET-inhibiting drugs by Neelesh Sharma, Alex A. Adjei

    Published 2011
    Get full text
    Artigo
    Save to List
    Saved in:
  20. 20
    Preclinical evaluation of dasatinib alone and in combination with cabozantinib for the treatment of diffuse intrinsic pontine glioma

    Preclinical evaluation of dasatinib alone and in combination with cabozantinib for the treatment of diffuse intrinsic pontine glioma by Nathalène Truffaux, Cathy Philippe, Janna Paulsson, Felipe Andreiuolo, Léa Guerrini‐Rousseau, Gaétan Cornilleau, Ludivine Le Dret, Catherine Richon, Ludovic Lacroix, Stéphanie Puget, Birgit Geoerger, Gilles Vassal, Arne Östman, Jacques Grill

    Published 2014
    Get full text
    Artigo
    Save to List
    Saved in:

Search Tools: